Clinical Trial Update: Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Phase 2 study of tipifarnib in high-risk myelodysplastic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED